Seres Therapeutics, Inc. (MCRB)

Seres Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	5.7	0.14	-113.72	-250.16	-65.58
Depreciation & Amortization	4.13	5.47	6.24	6.63	5.95
Stock-Based Compensation	10.84	20.97	34.1	25.48	20.22
Other Adjustments	8.23	-109.68	15	7.62	4.57
Change in Receivables	1.55	-2.07	-	-	-
Changes in Inventories	-	-33.8	-29.65	-	9.39
Changes in Accounts Payable	-2.4	-2.94	-11.58	2.2	9.36
Changes in Accrued Expenses	-20.98	-25.9	15.84	3.34	43.03
Changes in Unearned Revenue	-	-4.12	6.41	-7.13	-4.36
Changes in Other Operating Activities	-5.95	3.32	-40	-16.8	-15.89
Operating Cash Flow	1.12	-148.61	-117.35	-228.82	6.69
Capital Expenditures	-0.25	-0.38	-7.98	-9.82	-9.57
Sale of Property, Plant & Equipment	0.21	-	-	-	-
Purchases of Investments	-	-	-4.43	-48.22	-95.97
Proceeds from Sale of Investments	-	1.4	22.98	140.47	169.63
Proceeds from Business Divestments	-	141.27	-	-	-
Investing Cash Flow	-0.04	142.29	10.58	82.43	64.09
Long-Term Debt Issued	-	-	103.38	27.61	-
Long-Term Debt Repaid	-	-127.91	-52.86	-1.91	-0.95
Net Long-Term Debt Issued (Repaid)	-	-127.91	50.52	25.7	-0.95
Issuance of Common Stock	13.9	37.53	21.19	103.9	2.13
Net Common Stock Issued (Repurchased)	13.9	37.53	21.19	103.9	2.13
Financing Cash Flow	13.9	-90.37	71.71	129.6	1.18
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-	-0	0	-0	-0
Net Cash Flow	14.97	-96.69	-35.07	-16.79	71.95
Free Cash Flow	0.87	-148.99	-125.33	-238.64	-2.88
FCF Margin	109.63%	-	-	-	-1.99%
Free Cash Flow Per Share	0.10	-19.18	-19.58	-44.16	-0.63
Levered Free Cash Flow	-19.75	-186.12	-123.92	-109.61	-28.62
Unlevered Free Cash Flow	-119.42	-179.67	-255.81	-216.68	-26.58

Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q